Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TACR1 | P25103 | 15/20 | 0.58 |
| ▸ | CACNA1F | O60840 | 1/20 | 0.46 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.46 |
| ▸ | CACNA1D | Q01668 | 1/20 | 0.46 |
| ▸ | CACNA1S | Q13698 | 1/20 | 0.46 |
| ▸ | CACNA1C | Q13936 | 1/20 | 0.46 |
| ▸ | TMEM97 | Q5BJF2 | 1/20 | 0.46 |
| ▸ | GPR65 | Q8IYL9 | 1/20 | 0.46 |
| ▸ | NPC1 | O15118 | 1/20 | 0.46 |
| ▸ | MTOR | P42345 | 1/20 | 0.46 |
| ▸ | RAB9A | P51151 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9767413 | 0.88 | TACR1 (0.56) | TACR1CACNA1FCHRM5CACNA1DCACNA1S | |
| SCHEMBL9321841 | 0.88 | TACR1 (0.56) | TACR1CACNA1FCHRM5CACNA1DCACNA1S | |
| SCHEMBL9323196 | 0.86 | TACR1 (0.54) | TACR1CACNA1FCHRM5CACNA1DCACNA1S | |
| SCHEMBL9325160 | 0.84 | TACR1 (0.53) | TACR1 | |
| SCHEMBL9324308 | 0.83 | TACR1 (0.52) | TACR1 | |
| SCHEMBL8461669 | 0.83 | TACR1 (0.52) | TACR1 | |
| SCHEMBL8461665 | 0.83 | TACR1 (0.52) | TACR1 | |
| SCHEMBL9322791 | 0.83 | TACR1 (0.52) | TACR1 | |
| SCHEMBL9323071 | 0.82 | TACR1 (0.52) | TACR1 | |
| SCHEMBL9767509 | 0.82 | TACR1 (0.52) | TACR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0409931-B1 | QUINUCLIDINE THERAPEUTIC AGENTS | PFIZER (US) | 1994-02-16 | — | — | EP | disclosed |
| US-5162339-A | Substance P Antagonists, Gastrointestinal and Central Nervous System Disorders, Antiinflammatory Agents, Analgesics | PFIZER INC. (US) | 1992-11-10 | — | — | US | disclosed |